Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Health Care Up as Growth-to-Value Rotation Slows -- Health Care Roundup

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/30/2019 | 04:54pm EST

Health-care companies rose as traders rotated back into one of the sectors that lagged the market in the third quarter.

Momentum stocks such as biotechnology were out of favor during much of September as investors rotated into value stocks.

On Monday, many growth stocks were in the green. GlaxoSmithKline ticked up after the drug maker said promising results from a study of a cancer drug in a late-stage clinical trial on ovarian cancer patients vindicated its acquisition of cancer specialist Tesaro.

Write to Rob Curran at rob.curran@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
06:49aSANOFI WEIGHING OPTIONS FOR CONSUMER : sources
RE
11/18EUROPE : European stocks end flat as defensive gains offset auto slide
RE
11/15GLAXOSMITHKLINE : Nucala succeeds in phase three hypereosinophilic syndrome stud..
AQ
11/14LONDON STOCK EXCHANGE : FTSE 100 underperforms global peers on 3i drop, sterling..
RE
11/14GLAXOSMITHKLINE : Nucala is the first treatment to show a significant reduction ..
AQ
11/14Merck KGaA raises 2019 guidance after Versum takeover
RE
11/14GLAXOSMITHKLINE : Ex-dividend day for interim dividend
FA
11/11ANDREW WITTY : UnitedHealth Group Names Andrew Witty as President
DJ
11/07GLAXOSMITHKLINE : EACS 2019 ViiV Healthcare to present 17 abstracts from its por..
AQ
10/31UK's winter election - What's in it for markets?
RE
More news
Financials (GBP)
Sales 2019 33 425 M
EBIT 2019 9 059 M
Net income 2019 4 382 M
Debt 2019 24 973 M
Yield 2019 4,71%
P/E ratio 2019 18,8x
P/E ratio 2020 15,7x
EV / Sales2019 3,26x
EV / Sales2020 3,04x
Capitalization 83 966 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 813,39  GBp
Last Close Price 1 696,60  GBp
Spread / Highest target 29,7%
Spread / Average Target 6,88%
Spread / Lowest Target -11,0%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE13.77%108 446
JOHNSON & JOHNSON4.47%357 777
ROCHE HOLDING AG24.03%260 609
MERCK AND COMPANY10.78%217 096
NOVARTIS20.08%205 050
PFIZER-15.12%205 039